Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 53
Filtrer
3.
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;77(3): 208-214, Mar. 2019. graf
Article de Anglais | LILACS | ID: biblio-1001340

RÉSUMÉ

ABSTRACT The present article provides the historical background of the Sociedade Brasileira de Doenças Cerebrovasculares (Brazilian Society for Cerebrovascular Diseases), including details on its function, structure, challenges and main achievements.


RESUMO O presente texto apresenta um relato histórico da Sociedade Brasileira de Doenças Cerebrovasculares, incluindo detalhes da sua fundação, estruturação, dificuldades e principais realizações.


Sujet(s)
Humains , Histoire du 20ème siècle , Histoire du 21ème siècle , Sociétés médicales/histoire , Angiopathies intracrâniennes/prévention et contrôle , Sociétés médicales/organisation et administration , Sociétés médicales/tendances , Brésil , Recommandations comme sujet
5.
Rev. chil. obstet. ginecol. (En línea) ; Rev. chil. obstet. ginecol;83(5): 527-550, nov. 2018. tab, graf
Article de Espagnol | LILACS | ID: biblio-978127

RÉSUMÉ

ABSTRACT In the last decade, the risk benefits ratio of MHT has been evaluated mainly in terms of cardiovascular risk. Present Consensus Statement is largely inspired by the Global Consensus on Menopausal Hormone Therapy in 2013 and 2016 by leading global menopause societies (The American Society for Reproductive Medicine, The Asia Pacific Menopause Federation, The Endocrine Society, The European Menopause and Andropause Society, The International Menopause Society, The International Osteoporosis Foundation and The North American Menopause Society). The aim of these Recommendations is to provide a simple and updated reference on postmenopausal MHT. The term MHT typically includes estrogen replacement therapy (ERT) and estrogen-progestogen therapy (EPT). EPT can be sequential (Seq) when progestogen is added to ERT for 10-14 days a month, or continuous combined (CC) when progestogen is administered continuously every day along with a fixed amount of estrogen. MHT also includes Tibolone and the Tissue Selective Estrogen Complex (TSEC).


Sujet(s)
Humains , Femelle , Sociétés médicales/tendances , Ménopause , Oestrogénothérapie substitutive , Oestrogénothérapie substitutive/effets indésirables , Facteurs de risque , Oestrogènes/administration et posologie
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE